“We need to be having more conversations about menopause”
Women and Parkinson's
Author: Heather KennedyPublished: 28 November 2019
Prep: Cook: Serves:
Heather Kennedy, a writer, advocate and mother who
lives near San Francisco, US, lays bare the physical and emotional challenges
of managing the onset of menopause with Parkinson’s – from the night sweats and
a decreasing interest in sex to the sense of “turning inwards”
I was first diagnosed with Parkinson’s in 2011, at the age
As I approach the menopause, I’ve noticed changes in
myself. First of all, I have a lower libido. I just want nothing to do with sex
at the moment, which is unusual! Secondly, I find myself turning inwards. I
find myself getting quieter and retreating into my shell, which means I’m
further isolating myself inside this condition. I implore women with
Parkinson’s to make sure you connect with other women at this time in your life
– talk to one another, come together. We need to be having way more
conversations about menopause, and particularly about how menopause affects
women with Parkinson’s. This getting smaller, this sense of receding as a
person – it’s the opposite of what people with Parkinson’s should be doing.
I never questioned how the condition might affect me as a woman until I started experiencing unexplainable off times in the days leading up to my periods. I was complaining to my girlfriends, when one friend schooled me. She explained that during periods the efficacy of women’s medication decreases. No one had ever told me that! I then started to notice the pattern like clockwork. Since being perimenopausal, though, my periods have become far more unpredictable in heaviness and length.
“That just doesn’t
I have started to sweat through my sheets every night. I
was unsure if it was a result of my medication or because of the menopause, and
that’s the problem – none of these changes happen inside a vacuum. It’s not like
I can pinpoint that ‘this thing is caused by hormonal changes’ and ‘this part
is caused by medication’. All of these things melt into one so it’s hard to
tell what’s happening to my body. Most of the time the doctors can’t tell.
I tried to ask my doctor if the night sweats could be
because of the menopause. He insisted I was too young – even though at 49 I
don’t think I am – and just told me to see my gynaecologist. Though he is
usually patient, I was a little surprised at how he brushed me off.
There are other ways my progressing Parkinson’s affects me as a woman, urinary incontinence being one. Sometimes I’m too stubborn to wear a pad – I’d rather pee in my pants than wear a big honking mattress between my legs! That just doesn’t feel sexy! I suppose getting old in itself makes you feel a little less juicy but combine that with the symptoms associated with this condition – and the onset of menopause – and it’s fair to say I feel a little more insecure these days. Dating men has made that harder too. As soon as I say I have Parkinson’s, I never hear from them again.
One thing I’ve noticed in the Parkinson’s community is how women are openly shamed for experiencing impulse control disorders to do with sex (hyper compulsion being a side effect from our Parkinson’s medication) but when it’s men you hear that phrase: ‘Boys will be boys’. I just think that dynamic is so wrong. I experienced hyper compulsion but in my case it was with cleaning and shopping. I got very intense about cleaning out the closet – my daughter said, ‘Mum, you’ve been cleaning the closet for three days’. These drugs are powerful, and they cause major changes in us. We need more warning about that.
Need to know: Heather Kennedy– whose pen name is Kathleen Kiddo – is a writer, speaker and Parkinson’s advocate who was diagnosed with Parkinson’s in 2011 at the age of 41. She lives with her two children in California, US. Heather is publishing two new books, one on grief and the other a collection of short stories, in the coming year.
Parkinson’s and menopause: the facts
Common side-effects of menopause can often be confused with Parkinson’s symptoms
Currently there isn’t enough research on women with Parkinson’s for doctors to know whether to recommend the use of hormone replacement therapy (HRT)
A study involving a group of women with Parkinson’s aged 35 to 59 revealed that many were anxious about their bodies and sexual image – unfortunately such concerns are rarely addressed by doctors
It is estimated that three million women worldwide are living with Parkinson’s – yet their specific needs and experiences are often ignored, leading to disparities in diagnosis, treatment and medication. Each week, we’ll be sharing the little-heard stories of women with the condition to find out how their lives are being affected by a shocking data gap when it comes to women and Parkinson’s. This is just the start.
We want to raise awareness of women’s experience of the condition within the medical profession, so that women’s symptoms are taken seriously.
We think more research is needed into the impact of Parkinson’s on women, so that they can benefit from tailored medication and treatment.
We want to explore ways to offer better support for those women managing the condition alongside caring responsibilities.
Join us – #WomenAndParkinsons.
For more information on women and Parkinson’s please visit the EPDA website.
If you have a story to tell about being a woman with Parkinson’s – or some information about the impact of the condition on women for us to share with the global Parkinson’s community – please get in touch.
New brain chemical pump is “huge step forward” for advanced Parkinson’s
Approval of new dopamine pump welcomed by campaigners
2 days ago
New wearable medical device for Parkinson’s disease to launch this year
The Imperial College London Innovation Fund, UK, has invested £205,000 to support UK-based tech company Charco Neurotech in its development of a non-invasive medical device for people with Parkinson’s disease. CUE1, a circular device that attaches to the sternum with medical adhesives, uses specialised vibration to help alleviate physical symptoms of Parkinson’s disease. Initial user testing among people with the condition found that the device improved movement by an average of 16%, with testers reporting benefits for walking and fine motor tasks. Lucy Jung, CEO and co-founder of Charco Neurotech, said: “We believe that CUE1 has the potential to significantly improve [Parkinson’s disease] symptoms through its unique controlled vibration technology. We are excited to continue our work on the device and we look forward to the outcome of our proposed clinical trials.” Charco Neurotech will use the Imperial College investment to initiate a clinical trial and fund the device’s manufacture for…
New study brings scientists a “vital step” closer to understanding Parkinson’s disease
A new study from scientists at the University of Cambridge, UK, has brought researchers “a vital step” closer to discovering the origins of Parkinson’s disease. The research, published in the scientific journal ‘Nature Communications’, offered insights on the protein alpha-synuclein, which clumps together in the neurons of people with Parkinson’s. The study focused on how the protein functions in those without the condition and revealed that it sticks to the inner side of the plasma membrane of nerve cells, but not the outer membrane – an insight that could help in the search for a cure. Lead study author, Dr Giuliana Fusco, said: “This study could unlock more information about this debilitating neurodegenerative disorder that can leave people unable to walk and talk. If we want to cure Parkinson’s, first we need to understand the function of alpha-synuclein, a protein present in everyone’s brains.”
Could a prostate drug lower the risk of Parkinson’s disease?
Researchers in the US, Denmark and China have found that a type of medication used to treat enlarged prostate, known as alpha-blockers, is associated with a lower risk of Parkinson’s disease. As part of the study, the research team analysed patient data from 150,000 men using medications like the alpha-blocker terazosin – which has previously been shown to slow Parkinson’s disease progression in animals – and compared their findings to data from 150,000 men using the alpha-blocker tamsulosin. They found that men taking terazosin were 12 to 37% less likely to develop Parkinson’s disease. Jacob Simmering, corresponding author of the study, said: “Despite the relative differences in population and health care system structure, we found a similar protective effect in both [the US and Denmark]. “If these results are confirmed through further investigation, especially a randomised clinical trial, terazosin may provide neuroprotection and potentially prevent – and not just manage…